Production (Stage)
Amneal Pharmaceuticals, Inc.
AMRX
$7.16
-$0.03-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 695.42M | 730.52M | 702.47M | 701.78M | 659.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 695.42M | 730.52M | 702.47M | 701.78M | 659.19M |
| Cost of Revenue | 441.30M | 468.58M | 434.88M | 452.88M | 422.12M |
| Gross Profit | 254.12M | 261.94M | 267.59M | 248.91M | 237.08M |
| SG&A Expenses | 118.29M | 128.69M | 118.69M | 116.46M | 112.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.12M | -- | -- | -- | 100.00K |
| Total Operating Expenses | 594.50M | 651.53M | 614.67M | 605.39M | 574.11M |
| Operating Income | 100.92M | 78.99M | 87.80M | 96.39M | 85.08M |
| Income Before Tax | 37.49M | -15.32M | 15.42M | 20.41M | -75.52M |
| Income Tax Expenses | 12.87M | 5.42M | 3.67M | 3.62M | 6.16M |
| Earnings from Continuing Operations | 24.62M | -20.74M | 11.76M | 16.79M | -81.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.42M | -10.34M | -11.91M | -10.79M | -9.97M |
| Net Income | 12.20M | -31.08M | -156.00K | 5.99M | -91.64M |
| EBIT | 100.92M | 78.99M | 87.80M | 96.39M | 85.08M |
| EBITDA | 161.08M | 145.12M | 146.76M | 151.96M | 140.61M |
| EPS Basic | 0.04 | -0.10 | 0.00 | 0.02 | -0.30 |
| Normalized Basic EPS | 0.04 | -0.07 | -0.01 | 0.00 | 0.01 |
| EPS Diluted | 0.04 | -0.10 | 0.00 | 0.02 | -0.30 |
| Normalized Diluted EPS | 0.04 | -0.07 | -0.01 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 311.05M | 309.85M | 309.65M | 309.12M | 307.28M |
| Average Diluted Shares Outstanding | 323.96M | 309.85M | 309.65M | 318.96M | 307.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |